Goldman Sachs Group Inc Provention Bio, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$6.7 - $24.21 $4.32 Million - $15.6 Million	644,811 Added 294.07%	864,081 $20.8 Million
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $4.32 Million - $15.6 Million	644,811 Added 294.07%	864,081 $20.8 Million
Q4 2022 May 14, 2024	SELL	$4.52 - $10.57 $27,359 - $63,980	-6,053 Reduced 2.69%	219,270 $2.32 Million
Q4 2022 Feb 13, 2023	SELL	$4.52 - $10.57 $27,359 - $63,980	-6,053 Reduced 2.69%	219,270 $2.32 Million
Q3 2022 May 14, 2024	SELL	$3.43 - $5.62 $399,210 - $654,100	-116,388 Reduced 34.06%	225,323 $1.01 Million
Q3 2022 Nov 10, 2022	SELL	$3.43 - $5.62 $399,210 - $654,100	-116,388 Reduced 34.06%	225,323 $1.01 Million
Q2 2022 May 14, 2024	BUY	$3.65 - $7.3 $1.25 Million - $2.49 Million	341,711 New	341,711 $1.37 Million
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $357,773 - $715,546	98,020 Added 40.22%	341,711 $1.37 Million
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $88,022 - $204,005	-25,889 Reduced 9.6%	243,691 $1.78 Million
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $337,317 - $445,934	60,343 Added 28.84%	269,580 $1.52 Million
Q3 2021 Nov 10, 2021	BUY	$5.66 - $8.33 $1.18 Million - $1.74 Million	209,237 New	209,237 $1.34 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.